AVRN Blow Up !!!!
Wednesday, April 18, 2007
Chart courtesy of stockchartsAvanir Pharmaceuticals stock soar more than 300% closing at 5.19$ after the company said its drug candidate Zenvia reduced pain due to nerve damage in diabetes patients during a late-stage trial.
In a late-stage clinical trial, patients with diabetic neuropathic pain were given Zenvia or placebo and asked to make daily journals entries rating their pain. Avanir said patients given Zenvia reported significantly less pain in their journals over 90 days, thereby reaching the primary endpoint of the trial. Good news for stock.
Disclaimer : Trading stocks involves risk, this information should not be viewed as trading recommendations.The charts provided here are not meant for investment purposes and only serve as technical examples.
In a late-stage clinical trial, patients with diabetic neuropathic pain were given Zenvia or placebo and asked to make daily journals entries rating their pain. Avanir said patients given Zenvia reported significantly less pain in their journals over 90 days, thereby reaching the primary endpoint of the trial. Good news for stock.
Disclaimer : Trading stocks involves risk, this information should not be viewed as trading recommendations.The charts provided here are not meant for investment purposes and only serve as technical examples.
